论文部分内容阅读
Objective: No standard first-line treatment exists for patients with metastatic TNBC (mTNBC).In this single-arm, phase Ⅱ study (NCT00601159), we assessed the efficacy and tolerability of doublet with cisplatin and gemcitabine as first-line therapy in mTNBC.Method: Eligible women were those who had measurable disease with no prior chemotherapy for mTNBC.All patients received 21-day-cycle of cisplatin 25 mg/m2 on days 1-3 and gemcitabine 1,000mg/m2 on days 1 and 8.